Last reviewed · How we verify
Contrast enhanced ultrasound with Lumason
At a glance
| Generic name | Contrast enhanced ultrasound with Lumason |
|---|---|
| Also known as | Ultrasound |
| Sponsor | Indiana University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors (PHASE2)
- Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation (PHASE2)
- Effectiveness of Contrast-Enhanced Ultrasound (PHASE4)
- Contrast-Enhanced Ultrasound for Kidney Transplant (PHASE1)
- Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI). (EARLY_PHASE1)
- Y-90 Treatment Response Using Transarterial Radioembolization (PHASE2)
- Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy (NA)
- Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |